Clinical trials · Washington, D.C., DC
Prostate cancer clinical trials in Washington, D.C.
We’re tracking 114 recruiting prostate cancer studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT06863272RecruitingPhase 1/Phase 2
Study of ifinatamab deruxtecan for advanced prostate cancer
This trial tests a new drug, ifinatamab deruxtecan, either alone or in combination with other treatments, for men with metastatic castrate-resistant prostate cancer that has worsened despite hormone therapy. It aims to see if this approach can help shrink or slow the cancer.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05919264RecruitingPhase 1/Phase 2
FOG-001 for advanced solid tumors with certain gene changes
This trial tests a new drug, FOG-001, alone or with other treatments, for people with advanced solid tumors that have specific changes in the WNT pathway genes. It aims to see if the drug can shrink tumors or slow their growth.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04423211RecruitingPhase 3
Surgery-recovered prostate cancer treated with PET-guided radiation
This trial tests whether adding targeted radiation guided by a PET scan (along with hormone therapy) can improve outcomes for prostate cancer that has come back after surgery. The PET scan helps doctors look for spots outside the usual radiation area so treatment can be tailored.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05946213RecruitingPhase 3
Shorter radiation treatment for high-risk prostate cancer
This trial tests whether a shorter course of radiation works as well as the usual longer course for people with high-risk prostate cancer. The goal is to keep cancer control while possibly reducing treatment time and inconvenience.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04787744RecruitingPhase 2/Phase 3
Test standard prostate cancer treatment with or without targeted spot radiation
This study tests whether adding targeted local treatment (like radiation to a few spots seen on scans) improves outcomes for some people with limited (oligometastatic) prostate cancer. It compares standard systemic therapy alone versus standard therapy plus PET-scan–guided spot treatment.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05792722Recruiting
Testing a prostate-sparing bladder surgery for bladder cancer
This trial studies whether a “prostate-sparing” radical cystectomy is safe and effective for bladder cancer patients who are having surgery. It aims to see if this approach can treat bladder cancer while reducing prostate-related side effects.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04038502RecruitingPhase 2
Testing carboplatin or olaparib for gene-linked prostate cancer
This Phase 2 study tests whether carboplatin or olaparib can help people with prostate cancer that has certain DNA repair gene changes. It’s designed for advanced (metastatic) prostate cancer that is growing despite standard hormone-blocking treatment.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06798558RecruitingPhase 2
Lu-PSMA before prostate surgery for high-risk cancer
This trial tests a treatment called Lu-177-PSMA-617 given before surgery for high-risk prostate cancer that has spread only to nearby lymph nodes. It aims to see if this approach helps control the cancer before the prostate is removed.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06610825RecruitingPhase 2
Enhertu for prostate cancer resistant to hormone therapy
This trial is testing a drug called Enhertu for men whose prostate cancer has spread and is no longer responding to hormone treatments. You may join if you have a tumor sample that can be tested for a protein called HER2.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05155501Recruiting
Surgery planning approaches for localized prostate cancer
This study compares different approaches used during prostate cancer surgery for men whose cancer is only in the prostate. It may help doctors choose the safest and most effective surgical plan for your situation.
Washington D.C., District of ColumbiaAges 40–80 - NCT06764485RecruitingPhase 3
Comparing a new drug to standard therapy for advanced prostate cancer
This trial tests a new medicine (BMS-986365) against the doctor's choice of standard therapy for men with metastatic castration-resistant prostate cancer. It aims to see which treatment works better and is safer.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07128927Recruiting
Web-based insomnia treatment for prostate cancer survivors
This trial tests a web-based program to help Black/African American men with prostate cancer who have trouble sleeping. You'll learn strategies to improve your sleep without using medication.
Washington D.C., District of ColumbiaAges 21 years+ - NCT05803941RecruitingPhase 4
Study long-term safety of a prostate cancer drug
This trial checks the long-term safety (how it affects you over time) of lutetium-177 vipivotide tetraxetan in people with prostate cancer. You may be eligible if you already received the related drug in a prior Novartis prostate cancer study and can complete the required follow-up tests.
Washington D.C., District of ColumbiaAges 18–100 - NCT06398639Recruiting
Using genetic risk and MRI to find dangerous prostate cancer
This study uses a genetic risk score and a special MRI scan to find prostate cancers that are more likely to be dangerous. It aims to see if combining these tests can better identify which men need a biopsy.
Washington D.C., District of ColumbiaAges 40–69 - NCT03678025RecruitingPhase 3
Standard treatment for metastatic prostate cancer, with or without local treatment
This Phase 3 trial studies whether using the usual medicines for metastatic prostate cancer, plus a definitive local treatment to the prostate, improves outcomes. It may help determine if treating the prostate directly can benefit people whose cancer has not worsened after initial hormone-based treatment.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06136650RecruitingPhase 3
Study of a new drug for advanced prostate cancer
This study tests a new oral drug called opevesostat against another standard hormone therapy for men with advanced prostate cancer that has spread and is no longer controlled by a first hormone therapy. It's for men who have not had chemotherapy for this stage and who have not used a PARP inhibitor or chose not to.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07644598RecruitingPhase 2
Targeted Radiation Therapy for Low to Intermediate Risk Prostate Cancer
This study tests a new radiation treatment approach that uses MRI imaging to target specific tumor areas within the prostate while reducing radiation to healthy tissue. It may help patients with early-stage prostate cancer get effective treatment with fewer side effects.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06931340RecruitingPhase 3
Adding chemo to hormone therapy for advanced prostate cancer
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Washington D.C., District of ColumbiaAges 40–75 - NCT06592924RecruitingPhase 3
Adding chemo to hormone therapy for prostate cancer with slow PSA drop
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
Washington D.C., District of ColumbiaAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07164443RecruitingPhase 3
Study comparing pasritamig to placebo for advanced prostate cancer
This trial tests a new drug called pasritamig against a placebo for people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. The goal is to see if pasritamig can help slow the cancer's growth.
Washington D.C., District of ColumbiaAges 18 years+
Hear when a new Prostate cancer trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Prostate cancer trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting prostate cancer studies listed above.
- Sibley Memorial Hospital · 6 studies
- Georgetown University Medical Center · 5 studies
- Washington DC VA Medical Center · 5 studies
- George Washington University Hospital · 4 studies
- MedStar Georgetown University Hospital · 4 studies
- MedStar Washington Hospital Center · 4 studies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 4 studies
- Johns Hopkins University · 3 studies
What taking part in a prostate cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting prostate cancer studies in District of Columbia.
Common questions
- Are there prostate cancer clinical trials near Washington, D.C.?
- Yes. We're currently tracking 114 recruiting prostate cancer studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a prostate cancer study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a prostate cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New prostate cancer studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.